Skip to main
BAX
BAX logo

Baxter (BAX) Stock Forecast & Price Target

Baxter (BAX) Analyst Ratings

Based on 9 analyst ratings
Hold
Strong Buy 0%
Buy 22%
Hold 67%
Sell 11%
Strong Sell 0%

Bulls say

Baxter International demonstrated solid growth in its Healthcare Systems & Technologies segment, with year-over-year sales increases of approximately 6% in Q1 2025 and 2% in Q2 2025, alongside projected sales growth of about 4% and 2% in Q3 and Q4 2025, respectively. The company’s strategic acquisition of Hillrom in late 2021 has diversified its product portfolio, enhancing its presence in the hospital equipment market. Additionally, management's implementation of pricing initiatives is expected to yield a positive impact on sales growth of roughly 100 basis points for 2024 and 2025, further contributing to a favorable financial outlook.

Bears say

Baxter International's second-quarter 2025 performance was marked by disappointing results, as sales, margins, and earnings per share fell short of consensus expectations. The company has faced a challenging period from 2021 to 2023 due to both external factors and operational missteps, which have resulted in inconsistent quarterly performances and negative guidance revisions. Additionally, gross margins of 40.7% and operating margins of 15.1% were significantly below consensus estimates, driven by sales softness, manufacturing inefficiencies, and an unfavorable product mix.

Baxter (BAX) has been analyzed by 9 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 22% recommend Buy, 67% suggest Holding, 11% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Baxter (BAX) Forecast

Analysts have given Baxter (BAX) a Hold based on their latest research and market trends.

According to 9 analysts, Baxter (BAX) has a Hold consensus rating as of Nov 27, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Baxter (BAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.